参考文献/References:
[1] Dukkipati SR,Koruth JS,Choudry S,et al. Catheter ablation of ventricular tachycardia in structural heart disease:indications,strategies,and outcomes—Part Ⅱ[J]. J Am Coll Cardiol,2017,70(23):2924-2941.
[2] G?ko?lan Y,Mohanty S,Gianni C,et al. Scar homogenization versus limited-substrate ablation in patients withnonischemic cardiomyopathy andventricular tachycardia[J]. J Am Coll Cardiol,2016,68(18):1990-1998.
[3] Soto-Iglesias D,Penela D,Jáuregui B,et al. Cardiac magnetic resonance-guided ventricular tachycardia substrate ablation[J]. JACC Clin Electrophysiol,2020,6(4):436-447.
[4] Quinto L,Sanchez-Somonte P,Alarcón F,et al. Ventricular tachycardia burden reduction after substrate ablation:predictors of recurrence[J]. Heart Rhythm,2021,18(6):896-904.
[5] Cronin EM,Bogun FM,Maury P,et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias:executive summary[J]. Europace,2020,22(3):450-495.
[6] de Bakker JM,van Capelle FJ,Janse MJ,et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation[J]. Circulation,1988,77(3):589-606.
[7] Kotake Y,Nalliah CJ,Campbell T,et al. Comparison of the arrhythmogenic substrate for ventricular tachycardia in patients with ischemic vs non-ischemic cardiomyopathy—Insights from high-density,multi-electrode catheter mapping[J]. J I nterv C ard E lectrophysiol,2023,66(1):5-14.
[8] Aboud AA,Davogustto G,Adeola O,et al. Substrate mapping alters ventricular tachycardia inducibility[J]. Circ Arrhythm Electrophysiol,2023,16(2):66-73.
[9] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur H eart J,2021,42(5):373-498.
[10] Codreanu A,Odille F,Aliot E,et al. Electroanatomic characterization of post-infarct scars comparison with 3-dimensional myocardial scar reconstruction based on magnetic resonance imaging[J]. J Am Coll Cardiol,2008,52(10):839-842.
[11] Wijnmaalen AP,van der Geest RJ,van Huls van Taxis CF,et al. Head-to-head comparison of contrast-enhanced magnetic resonance imaging and electroanatomical voltage mapping to assess post-infarct scar characteristics in patients with ventricular tachycardias:real-time image integration and reversed registration[J]. Eur H eart J,2011,32(1):104-114.
[12] Piers SR,Tao Q,van Huls van Taxis CF,et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy:implications for the ablation strategy[J]. Circ Arrhythm Electrophysiol,2013,6(5):875-883.
[13] Acosta J,Fernández-Armenta J,Penela D,et al. Infarct transmurality as a criterion for first-line endo-epicardial substrate-guided ventricular tachycardia ablation in ischemic cardiomyopathy[J]. Heart Rhythm,2016,13(1):85-95.
[14] Ghannam M,Siontis KC,Cochet H,et al. Value of mapping and ablation of ventricular tachycardia targets within the coronary venous system in patients with nonischemic cardiomyopathy[J]. Heart Rhythm,2020,17(4):520-526.
[15] Hilbert S,Weber A,Nehrke K,et al. Artefact-free late gadolinium enhancement imaging in patients with implanted cardiac devices using a modified broadband sequence:current strategies and results from a real-world patient cohort[J]. Europace,2018,20(5):801-807.
[16] Siontis KC,Kim HM,Sharaf Dabbagh G,et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy[J]. Heart Rhythm,2017,14(10):1487-1493.
[17] Lilli A,Parollo M,Mazzocchetti L,et al. Ventricular tachycardia ablation guided or aided by scar characterization with cardiac magnetic resonance:rationale and design of VOYAGE study[J]. BMC Cardiovasc Disord,2022,22(1):169.
[18] Muser D,Nucifora G,Castro SA,et al. Myocardial substrate characterization by CMR T1 mapping in patients with NICM and no LGE undergoing catheter ablation of VT[J]. JACC Clin Electrophysiol,2021,7(7):831-840.
[19] Peretto G,Sala S,Basso C,et al. Inflammation as a predictor of recurrentventricular tachycardia after ablation in patients with myocarditis[J]. J Am Coll Cardiol,2020,76(14):1644-1656.
[20] Kaur D,Roukoz H,Shah M,et al. Impact of the inflammation on the outcomes of catheter ablation of drug-refractory ventricular tachycardia in cardiac sarcoidosis[J]. J Cardiovasc E lectrophysiol,2020,31(3):612-620.
[21] Hendriks AA,Kis Z,Glisic M,et al. Pre-procedural image-guided versus non-image-guided ventricular tachycardia ablation—A?review[J]. Neth H eart J,2020,28(11):573-583.
[22] Nazarian S,Kolandaivelu A,Zviman MM,et al. Feasibility of real-time magnetic resonance imaging for catheter guidance in electrophysiology studies[J]. Circulation,2008,118(3):223-229.
[23] Chubb H,Williams SE,Whitaker J,et al. Cardiac electrophysiology under MRI guidance:an emerging technology[J]. Arrhythm Electrophysiol Rev,2017,6(2):85-93.
[24] Mukherjee RK,Roujol S,Chubb H,et al. Epicardial electroanatomical mapping, radiofrequency ablation,and lesion imaging in the porcine left ventricle under real-time magnetic resonance imaging guidance—An in vivo feasibility study[J]. Europace,2018,20(FI2):f254-f262.
[25] Bauer BK,Meier C,Bietenbeck M,et al. Cardiovascular magnetic resonance-guided radiofrequency ablation:where are we now?[J]. JACC Clin Electrophysiol,2022,8(2):261-274.
[26] Paetsch I,Sommer P,Jahnke C,et al. Clinical workflow and applicability of electrophysiological cardiovascular magnetic resonance-guided radiofrequency ablation of isthmus-dependent atrial flutter[J]. Eur Heart J Cardiovasc Imaging,2019,20(2):147- 156.
[27] Guttman MA,Tao S,Fink S,et al. Non-contrast-enhanced T1-weighted MRI of myocardial radiofrequency ablation lesions[J]. Magn Reson Med,2018,79(2):879-889.
[28] Vunnam R,Maheshwari V,Jeudy J,et al. Ventricular arrhythmia ablation lesions detectability and temporal changes on cardiac magnetic resonance[J]. Pacing Clin Electrophysiol,2020,43(3):314-321.
[29] Dabbagh GS,Ghannam M,Siontis KC,et al. Magnetic resonance mapping of catheter ablation lesions after post-infarction ventricular tachycardia ablation[J]. JACC Cardiovasc Imaging,2021,14(3):588-598.
[30] Ghannam M,Liang J,Attili A,et al. Late gadolinium enhancement cardiac magnetic resonance imaging of ablation lesions after postinfarction ventricular tachycardia ablation:implications for ventricular tachycardia recurrence[J]. J Cardiovasc E lectrophysiol,2022,33(4):715-721.
[31] Dickfeld T,Vunnam R. Chronic ablation lesions on CMR:is black a red herring?[J]. JACC Cardiovasc I maging,2021,14(3):599-601.
[32] de la Pinta C,Besse R. Stereotactic ablative body radiotherapy for ventricular tachycardia:an alternative therapy for refractory patients[J]. Anat J Cardiol,2021,25(12):858-862.
[33] Russo RJ,Costa HS,Silva PD,et al. Assessing the risks associated with MRI in patients with a pacemaker or defibrillator[J]. N Engl J Med,2017,376(8):755-764.
[34] Roca-Luque I,van Breukelen A,Alarcon F,et al. Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators[J]. Europace,2020,22(4):598-606.
[35] Shusterman V,Hodgson-Zingman D,Thedens D,et al. High-energy external defibrillation and transcutaneous pacing during MRI:feasibility and safety[J]. J C ardiovasc M agn R eson,2019,21(1):47.
相似文献/References:
[1]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[2]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(1):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[3]徐源蔚 陈玉成.心脏磁共振在检测自身免疫性风湿疾病心脏受累中的应用进展[J].心血管病学进展,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
XU Yuanwei,CHEN Yucheng.Advances in the Application of Cardiac Magnetic Resonance in Detecting Cardiac Involvement in Autoimmune Rheumatic Disease[J].Advances in Cardiovascular Diseases,2019,(1):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
[4]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(1):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[5]冯泽豪 姜萌 卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
FENG Zehao,JIANG Meng,PU Jun.Cardiovascular Magnetic Resonance for Detection of Myocardial Impairments Caused by Chemotherapy[J].Advances in Cardiovascular Diseases,2019,(1):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
[6]金荣杰 徐勇 邓珏琳 沈明志.应用心脏磁共振评估前列地尔对ST段抬高型心肌梗死患者心肌灌注的影响[J].心血管病学进展,2020,(10):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
JIN RongjieXU YongDENG JuelinSHEN Mingzhi.Effect of Alprostadil on Myocardial Perfusion of Patients with ST Segment Elevation Myocardial Infarction Directly Receiving Percutaneous Coronary Intervention Assessed with Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(1):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
[7]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(1):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
[8]陈小玲 陈玉成.肺高压心肌纤维化磁共振评价及临床意义[J].心血管病学进展,2021,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
CHEN Xiaoling,CHEN Yucheng.Cardiac Magnetic Resonance Evaluation and the Clinical Value of Myocardial Fibrosis in Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(1):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
[9]李才垚 王洪涛 秦兴华 刘鹏 郑强荪.心肌梗死后室性心动过速导管消融适应证在指南共识中的演变[J].心血管病学进展,2021,(5):421.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.009]
LI Caiyao,WANG Hongtao,QIN Xinghua,et al.Evolution of Indications for Ablation of Ventricular Tachycardia after Myocardial Infarction in Guidelines and Consensus[J].Advances in Cardiovascular Diseases,2021,(1):421.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.009]
[10]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(1):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]